Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer

Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate without small cell features * Oligometastatic PCa assessed by Ga-68 prostate-specific membrane antigen (PSMA), PET/CT * \<4 bone oligometastases, lymph node metastasis below the renal artery level * Expected survival time \>5 years * World Health Organization (WHO) performance status 0-1 * Be willing to give written informed consent. Exclusion Criteria: * Any previous or ongoing treatment for PCa, including radiotherapy, ADT, chemotherapy, focal treatment, etc. * Patients who have previously undergone transurethral resection or enucleation of the prostate. * Patients who have undergone other abdominal surgery within the last 3 months * Patients who have visceral metastases * Patients with a history of long-term anticoagulant use and anti-platelet drug use and who stopped anticoagulant therapy less than 1 week before registration * Patients with other malignancies and acute or chronic infections such as human immunodeficiency virus (HIV) (+), hepatitis C virus (HCV) (+) and/or positive syphilis * Severe or active comorbidities likely to impact the advisability of radiotherapy * Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which, according to the judgement of the investigator, may affect the planned staging, treatment and follow-up or patient compliance or may cause high-risk treatmentrelated complications for the patient * Patients who have participated in other clinical trials within the last 3 months * Patients who refuse to undergo RALP * Patients unsuitable for participation in this clinical trial as per the judgement of the investigator.